文献速递关节外科

度洛西汀可减轻中枢敏化患者全膝关节置换术后疼痛并改善恢复质量:一项前瞻性随机对照研究

Duloxetine Reduces Pain and Improves Quality of Recovery Following Total Knee Arthroplasty in Centrally Sensitized Patients: A Prospective, Randomized Controlled Study.
PubMed 文献 · J Bone Joint Surg Am · 2019-01-01

该前瞻性随机对照研究纳入80例术前经中枢敏化量表(CSI)判定为中枢敏化的原发性单侧全膝关节置换术患者,度洛西汀组40例于术前1天及术后6周服用30 mg,对照组40例不用度洛西汀。度洛西汀组在术后2至12周疼痛指标更优(p<0.05),术后2周恢复质量更优(p<0.05),两组不良事件发生率无差异。

要点

  • 在464例拟行初次单侧全膝关节置换术的原发性骨关节炎患者中,80例被识别为中枢敏化并纳入研究。
  • 度洛西汀组术后2至12周疼痛指标优于对照组(p<0.05)。
  • 度洛西汀组术后2周恢复质量优于对照组(p<0.05),两组不良事件发生率无差异。

核心结论

  • 相当数量的患者在初次全膝关节置换术前已存在中枢敏化。
  • 作者认为,外科医生应根据中枢敏化严重程度,考虑将度洛西汀选择性纳入多模式术后镇痛方案,以尽量减少全膝关节置换术后持续疼痛的可能。

研究设计与样本

  • 前瞻性随机对照研究,证据等级为治疗性I级。
  • 在464例拟行初次单侧全膝关节置换术的原发性骨关节炎患者中,术前用中枢敏化量表(CSI)筛查出80例中枢敏化患者并纳入研究。
  • 40例随机分入度洛西汀组(术前1天及术后6周服用30 mg),40例随机分入对照组(不用度洛西汀)。
  • 用简明疼痛量表(BPI)、健康调查简表36(SF-36)、间歇性和持续性骨关节炎疼痛测量量表(ICOAP)及汉密尔顿抑郁量表评估疼痛与恢复质量,并记录药物不良事件发生率。

主要发现

  • 度洛西汀组在术后最初2至12周期间各项疼痛指标均优于对照组(p<0.05)。
  • 度洛西汀组术后2周恢复质量优于对照组,体现在情绪和躯体功能方面(所有p<0.05)。
  • 两组不良事件发生率无差异。

临床怎么用

  • 作者认为,外科医生应根据中枢敏化严重程度,考虑将度洛西汀选择性纳入多模式术后镇痛方案,以尽量减少全膝关节置换术后持续疼痛的可能。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Unexplained postoperative pain is one of the most feared complications of total knee arthroplasty (TKA). A persistent noxious peripheral stimulus, such as the pain of chronic knee osteoarthritis, can cause central sensitization in which the central nervous system becomes hyperexcitable, resulting in hypersensitivity to both noxious and non-noxious stimuli. Patients with central sensitization may be more susceptible to unexplained pain after TKA. Duloxetine, a selective serotonin norepinephrine reuptake inhibitor (SNRI), can ameliorate the pain associated with central sensitization, and we aimed to determine whether it could reduce postoperative pain and improve quality of recovery after TKA in patients with central sensitization. METHODS: Patients undergoing TKA were screened for central sensitization preoperatively with use of the Central Sensitization Inventory (CSI). Among 464 patients with primary osteoarthritis who were scheduled for primary unilateral TKA, 80 were identified as being centrally sensitized and were included in the study. Forty patients were randomly assigned to the duloxetine group (30 mg 1 day before surgery and for 6 weeks after surgery), and 40 were randomized to the control group (no duloxetine). Pain and quality of recovery were assessed with use of the Brief Pain Inventory (BPI), the Short Form-36 (SF-36), the Measure of Intermittent and Constant Osteoarthritis Pain (ICOAP), and the Hamilton Depression Scale. The prevalence of adverse medication effects was also noted. RESULTS: The patients in the duloxetine group had better performance across pain metrics during the initial 2 to 12-week postoperative period (p < 0.05). The duloxetine group also had a superior quality of recovery 2 weeks after TKA, as indicated by emotional and physical functioning (all p < 0.05). There was no difference between groups in the prevalence of adverse events. CONCLUSIONS: A substantial number of patients are centrally sensitized before TKA. Surgeons should consider selective incorporation of duloxetine into the multimodal postoperative analgesic protocol, according to the severity of central sensitization, to minimize the possibility of persistent pain following TKA. LEVEL OF EVIDENCE: Therapeutic Level I. See Instructions for Authors for a complete description of levels of evidence.

来源:J Bone Joint Surg Am,查看原文。版权归原作者所有。

引用

  1. Koh IJ, Kim MS, Sohn S, et al. Duloxetine Reduces Pain and Improves Quality of Recovery Following Total Knee Arthroplasty in Centrally Sensitized Patients: A Prospective, Randomized Controlled Study. J Bone Joint Surg Am. 2019. PMID: 30601417. doi:10.2106/JBJS.18.00347

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。